DK1890705T3 - Anvendelse af 24-nor-ursodeoxycholsyre til behandling af cholestatiske leversygdomme - Google Patents
Anvendelse af 24-nor-ursodeoxycholsyre til behandling af cholestatiske leversygdomme Download PDFInfo
- Publication number
- DK1890705T3 DK1890705T3 DK05749537.6T DK05749537T DK1890705T3 DK 1890705 T3 DK1890705 T3 DK 1890705T3 DK 05749537 T DK05749537 T DK 05749537T DK 1890705 T3 DK1890705 T3 DK 1890705T3
- Authority
- DK
- Denmark
- Prior art keywords
- bile
- norudca
- udca
- acid
- liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (4)
1. Farmaceutisk præparat indeholdende 24-nor-ursodeoxycholsyre og/eller farmaceutisk acceptable salte og methyl-, ethyl-, propyl-, isopropyl-, butyl-, isopropyl-, pentyl- eller aryl-estere deraf til anvendelse ved behandling og/eller forebyggelse af en cholestatisk leversygdom, hvor leversygdommen er valgt fra gruppen bestående af primære skleroserende cholangitis (PSC), primær biliær cirrhose (PBC) eller progressiv familiær intrahepatisk cholestasis type 3.
2. Præparat til anvendelse ifølge krav 1, kendetegnet ved at præparatet er formuleret til oral, parenteral, subkutan, intravenøs, intramuskulær, nasal, topisk eller rektal indgivelse.
3. Præparat til anvendelse ifølge krav 1 eller 2, kendetegnet ved, at præparatet omfatter en effektiv mængde af 24-nor-ursodeoxycholsyre, farmaceutisk acceptable salte eller estere deraf og mindst én farmaceutisk acceptabel bærer og/eller excipiens.
4. Præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 3, kendetegnet ved, at præparatet indeholder 10 til 8.000 mg, fortrinsvis 25 til 5.000 mg, mere fortrinsvis 50 til 1500 mg, især 250-500 mg, af 24-nor-ursodeoxycholsyre og/eller mindst et farmaceutisk acceptabelt salt og/eller ester deraf.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2005/052178 WO2006119803A1 (en) | 2005-05-12 | 2005-05-12 | USE OF 24-nor-UDCA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1890705T3 true DK1890705T3 (da) | 2016-02-01 |
Family
ID=35457032
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05749537.6T DK1890705T3 (da) | 2005-05-12 | 2005-05-12 | Anvendelse af 24-nor-ursodeoxycholsyre til behandling af cholestatiske leversygdomme |
| DK11176270.4T DK2392335T3 (en) | 2005-05-12 | 2005-05-12 | Use of 24-norUDCA |
| DK11176272.0T DK2392337T3 (da) | 2005-05-12 | 2005-05-12 | Anvendelse af nor-ursodeoxycholsyre |
| DK11176271.2T DK2392336T3 (da) | 2005-05-12 | 2005-05-12 | 24-norUDCA til behandling af autoimmun hepatitis |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11176270.4T DK2392335T3 (en) | 2005-05-12 | 2005-05-12 | Use of 24-norUDCA |
| DK11176272.0T DK2392337T3 (da) | 2005-05-12 | 2005-05-12 | Anvendelse af nor-ursodeoxycholsyre |
| DK11176271.2T DK2392336T3 (da) | 2005-05-12 | 2005-05-12 | 24-norUDCA til behandling af autoimmun hepatitis |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8951995B2 (da) |
| EP (4) | EP2392336B1 (da) |
| AU (1) | AU2005331734B2 (da) |
| CY (4) | CY1116831T1 (da) |
| DK (4) | DK1890705T3 (da) |
| EA (1) | EA014077B1 (da) |
| ES (4) | ES2561614T3 (da) |
| HK (1) | HK1161122A1 (da) |
| HR (3) | HRP20150949T1 (da) |
| HU (4) | HUE025184T2 (da) |
| LT (1) | LT2392336T (da) |
| ME (3) | ME02256B (da) |
| NO (1) | NO340318B1 (da) |
| PL (4) | PL2392335T3 (da) |
| PT (3) | PT2392337E (da) |
| RS (3) | RS54185B1 (da) |
| SI (4) | SI2392335T1 (da) |
| WO (1) | WO2006119803A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| EP2182954B1 (en) * | 2007-07-25 | 2018-11-28 | Medizinische Universität Graz | Use of nor-bile acids in the treatment of arteriosclerosis |
| EP2468762A1 (en) * | 2010-11-30 | 2012-06-27 | Dr. Falk Pharma Gmbh | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size |
| EP3461485A1 (en) | 2017-09-28 | 2019-04-03 | Dr. Falk Pharma Gmbh | Use of nor-ursodeoxycholic acid for reducing liver fat |
| GB201911821D0 (en) | 2019-08-16 | 2019-10-02 | Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid | Compounds for use in the treatment of liver disease |
| US11372809B2 (en) | 2019-09-27 | 2022-06-28 | Oracle International Corporation | System and method for providing correlated content organization in an enterprise content management system based on a training set |
| WO2021130232A1 (en) | 2019-12-23 | 2021-07-01 | Medizinische Universität Wien | Bile acid derivatives in the medical intervention of anxieties and/or stress symptoms |
| WO2024023669A1 (en) * | 2022-07-25 | 2024-02-01 | Shilpa Medicare Limited | Pharmaceutical compositions of nor-udca |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892868A (en) | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
| IT1229569B (it) * | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| IT1255449B (it) | 1992-06-30 | 1995-10-31 | Fabio Berlati | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. |
| TW289020B (da) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| ITMI20012572A1 (it) | 2001-12-06 | 2003-06-06 | Istituto Biochimico Italiano | Microgranuli di acido ursodesossicolico |
-
2005
- 2005-05-12 PT PT111762720T patent/PT2392337E/pt unknown
- 2005-05-12 PL PL11176270T patent/PL2392335T3/pl unknown
- 2005-05-12 ES ES05749537.6T patent/ES2561614T3/es active Active
- 2005-05-12 ME MEP-2016-198A patent/ME02256B/me unknown
- 2005-05-12 PL PL05749537T patent/PL1890705T3/pl unknown
- 2005-05-12 RS RS20150511A patent/RS54185B1/en unknown
- 2005-05-12 DK DK05749537.6T patent/DK1890705T3/da active
- 2005-05-12 PL PL11176271.2T patent/PL2392336T3/pl unknown
- 2005-05-12 DK DK11176270.4T patent/DK2392335T3/da active
- 2005-05-12 SI SI200531997T patent/SI2392335T1/sl unknown
- 2005-05-12 HU HUE11176270A patent/HUE025184T2/en unknown
- 2005-05-12 PL PL11176272T patent/PL2392337T3/pl unknown
- 2005-05-12 PT PT111762704T patent/PT2392335E/pt unknown
- 2005-05-12 AU AU2005331734A patent/AU2005331734B2/en not_active Ceased
- 2005-05-12 DK DK11176272.0T patent/DK2392337T3/da active
- 2005-05-12 RS RS20160771A patent/RS55180B1/sr unknown
- 2005-05-12 DK DK11176271.2T patent/DK2392336T3/da active
- 2005-05-12 LT LTEP11176271.2T patent/LT2392336T/lt unknown
- 2005-05-12 HU HUE11176272A patent/HUE025409T2/en unknown
- 2005-05-12 ES ES11176271.2T patent/ES2590333T3/es active Active
- 2005-05-12 SI SI200532036T patent/SI1890705T1/sl unknown
- 2005-05-12 HU HUE11176271A patent/HUE030010T2/en unknown
- 2005-05-12 EP EP11176271.2A patent/EP2392336B1/en active Active
- 2005-05-12 ES ES11176270.4T patent/ES2547127T3/es active Active
- 2005-05-12 SI SI200532003T patent/SI2392337T1/sl unknown
- 2005-05-12 ME MEP-2016-228A patent/ME02544B/me unknown
- 2005-05-12 EP EP05749537.6A patent/EP1890705B1/en active Active
- 2005-05-12 ES ES11176272.0T patent/ES2550204T3/es active Active
- 2005-05-12 US US11/914,211 patent/US8951995B2/en active Active
- 2005-05-12 EA EA200702336A patent/EA014077B1/ru not_active IP Right Cessation
- 2005-05-12 RS RS20150495A patent/RS54140B1/en unknown
- 2005-05-12 PT PT111762712T patent/PT2392336T/pt unknown
- 2005-05-12 EP EP11176270.4A patent/EP2392335B1/en active Active
- 2005-05-12 EP EP11176272.0A patent/EP2392337B1/en active Active
- 2005-05-12 SI SI200532092A patent/SI2392336T1/sl unknown
- 2005-05-12 HU HUE05749537A patent/HUE028336T2/en unknown
- 2005-05-12 WO PCT/EP2005/052178 patent/WO2006119803A1/en active Application Filing
- 2005-05-12 ME MEP-2015-495A patent/ME02737B/me unknown
-
2007
- 2007-12-12 NO NO20076405A patent/NO340318B1/no not_active IP Right Cessation
-
2012
- 2012-02-24 HK HK12101926.3A patent/HK1161122A1/xx not_active IP Right Cessation
-
2015
- 2015-09-08 HR HRP20150949TT patent/HRP20150949T1/hr unknown
- 2015-09-23 CY CY20151100834T patent/CY1116831T1/el unknown
- 2015-10-16 HR HRP20151091TT patent/HRP20151091T1/hr unknown
- 2015-10-21 CY CY20151100939T patent/CY1116840T1/el unknown
-
2016
- 2016-02-10 CY CY20161100107T patent/CY1117174T1/el unknown
- 2016-09-02 CY CY20161100863T patent/CY1117959T1/el unknown
- 2016-09-19 HR HRP20161197TT patent/HRP20161197T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1890705T3 (da) | Anvendelse af 24-nor-ursodeoxycholsyre til behandling af cholestatiske leversygdomme | |
| Chiang et al. | Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy | |
| US20200078374A1 (en) | Polyhydroxylated bile acids for treatment of biliary disorders | |
| Fiorucci et al. | Chenodeoxycholic acid: an update on its therapeutic applications | |
| KR20180115700A (ko) | Fxr 효능제를 사용하는 방법 | |
| JP5909774B2 (ja) | 胆道疾患を治療するためのポリヒドロキシル化胆汁酸 | |
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| JP2019530696A (ja) | 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物 | |
| US9884066B2 (en) | Bile acid-basic amino acid conjugates and uses thereof | |
| JP2018502854A (ja) | 疾患および障害を処置するためのカルシトニン類似体 | |
| Mikov et al. | Potentials and limitations of bile acids and probiotics in diabetes mellitus | |
| TW202135812A (zh) | 使用整聯蛋白抑制劑組合治療肝臟疾病 | |
| CN113874023A (zh) | 使用奥贝胆酸诊断和治疗肝病的方法 | |
| WO2005055997A1 (ja) | 炎症性疾患の治療及び予防用医薬組成物 | |
| WO2023210716A1 (ja) | Ｃｂｐ／カテニン阻害剤の肝線維症治療レジメン | |
| AU2022214948B2 (en) | Treatment of cholangiopathies with seladelpar | |
| WO2020240483A1 (en) | Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist | |
| NZ800627B2 (en) | Treatment of cholangiopathies with seladelpar | |
| Meyer | The pathophysiology of retained bile acids |